The new monthly injectables Cyclofem and Mesigyna are well-tested alternatives to older monthlies. Although the first injectables were developed soon after oral contraceptives, limited availability has constrained use in all but a few countries, such as Indonesia and Thailand. More than 100 countries have approved DMPA since the early 1960s, but political controversy and scientific uncertainty have held back injectables in some programs. The WHO research reduced fears about DMPA causing cancer. The User's Perspective Throughout the world many women value injectables because they are highly effective, long-acting, reversible, and convenient, and they can be used privately.
Women experience a variety of side effects with injectables, however.
Disruption of menstrual bleeding is common, and some women find it troublesome. Counseling helps women understand that the frequent or irregular bleeding and amenorrhea are not dangerous, and many continue to use injectables despite these bleeding changes. Also, some women using injectables report weight gain, headaches, and dizziness. Counsel to ensure informed choice and use. With information and encouragement from providers, women make their own choices among family planning methods.